Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 94
Tytuł:
Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort.
Autorzy:
Murahwa AT; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Mudzviti T; Newlands Clinic, Harare P.O. Box A178, Zimbabwe.; Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare P.O. Box AI78, Zimbabwe.
Mandishora RSD; Medical Microbiology Unit, Department of Laboratory Diagnostic and Investigative Sciences, University of Zimbabwe, Harare P.O. Box AI78, Zimbabwe.; Center for Immunization and Infection Research in Cancer, Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, 33612 FL, USA.
Chatindo T; Newlands Clinic, Harare P.O. Box A178, Zimbabwe.
Chanetsa P; Newlands Clinic, Harare P.O. Box A178, Zimbabwe.
Pascoe M; Newlands Clinic, Harare P.O. Box A178, Zimbabwe.
Shamu T; Newlands Clinic, Harare P.O. Box A178, Zimbabwe.; Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland.; Graduate School of Health Sciences, University of Bern, 3012 Bern, Switzerland.
Basera W; Burden of Disease Research Unit, South African Medical Research Council, Cape Town 7925, South Africa.
Luethy R; Newlands Clinic, Harare P.O. Box A178, Zimbabwe.
Williamson AL; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.; SAMRC Gynaecological Cancer Research Centre, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Jan 22; Vol. 16 (1). Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:
Journal Article
MeSH Terms:
Papillomavirus Infections*/epidemiology
Papillomavirus Infections*/prevention & control
Papillomavirus Vaccines*
Uterine Cervical Neoplasms*
HIV Infections*/complications
Humans ; Female ; Adolescent ; Child ; Male ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ; Cross-Sectional Studies ; Zimbabwe/epidemiology ; Vaccination ; Human papillomavirus 16 ; Human papillomavirus 18
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.
Autorzy:
Kiendrébéogo JA; Department of Public Health, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso. .; Recherche pour la santé et le développement (RESADE), Ouagadougou, Burkina Faso. .; Heidelberg Institute of Global Health, Medical Faculty and University Hospital, Heidelberg University, Heidelberg, Germany. .
Sidibe ARO; Directorate of Prevention through Immunization, Ministry of Health, Ouagadougou, Burkina Faso.; Jhpiego, Ouagadougou, Burkina Faso.
Compaoré GB; Radiotherapy Center of Bogodogo, Ouagadougou, Burkina Faso.
Nacanabo R; Institute of Health Sciences and Research (IRSS), Ouagadougou, Burkina Faso.
Sory O; Recherche pour la santé et le développement (RESADE), Ouagadougou, Burkina Faso.
Ouédraogo I; Directorate of Prevention through Immunization, Ministry of Health, Ouagadougou, Burkina Faso.
Nawaz S; PATH, Seattle, USA.
Schuind AE; PATH, Seattle, USA.
Clark A; London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy, London, UK.
Pokaż więcej
Źródło:
BMC health services research [BMC Health Serv Res] 2023 Dec 01; Vol. 23 (1), pp. 1338. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Journal Article
MeSH Terms:
Uterine Cervical Neoplasms*/epidemiology
Papillomavirus Infections*
Papillomavirus Vaccines*
Female ; Humans ; Child ; Cost-Benefit Analysis ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ; Human Papillomavirus Viruses ; Burkina Faso/epidemiology ; Early Detection of Cancer ; Vaccination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice.
Autorzy:
Chen CW; Department of Biomedical Sciences, University of Barcelona, 08036 Barcelona, Spain.; Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain.; Department of Microbiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Saubi N; Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain.; Department of Microbiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.; Respiratory Viruses Unit, Virology Section, Microbiology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Joseph-Munné J; Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain.; Department of Microbiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 29; Vol. 24 (9). Date of Electronic Publication: 2023 Apr 29.
Typ publikacji:
Journal Article
MeSH Terms:
HIV-1*
Papillomavirus Infections*
Oncogene Proteins, Viral*
Humans ; Animals ; Mice ; Human papillomavirus 16/genetics ; Human Papillomavirus Viruses ; Antibodies, Viral ; Mice, Inbred BALB C ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ; Peptides ; Capsid Proteins/chemistry ; Mammals
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Autorzy:
Cody P; Merck &Co., Inc., Kenilworth, NJ, USA. .; Center for Observational and Real-world Evidence (CORE), Merck & Co., Inc., WP37A-150, PO Box 1000, West Point, PA, 19486, USA. .
Tobe K; MSD.K.K., Tokyo, Japan.
Abe M; MSD.K.K., Tokyo, Japan.
Elbasha EH; Merck &Co., Inc., Kenilworth, NJ, USA.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2021 Jan 06; Vol. 21 (1), pp. 11. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji:
Journal Article
MeSH Terms:
Public Health*
Alphapapillomavirus/*immunology
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Immunization Programs/*economics
Papillomavirus Infections/*prevention & control
Uterine Cervical Neoplasms/*prevention & control
Vaccination/*economics
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Child, Preschool ; Cost-Benefit Analysis ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Incidence ; Infant ; Japan/epidemiology ; Male ; Middle Aged ; Models, Theoretical ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/transmission ; Papillomavirus Infections/virology ; Quality-Adjusted Life Years ; Uterine Cervical Neoplasms/virology ; Vaccination/methods ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study.
Autorzy:
Kurokawa T; Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka, Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan. .
Yamamoto M; Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka, Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
Onuma T; Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka, Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
Tsuyoshi H; Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka, Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
Shinagawa A; Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka, Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
Chino Y; Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka, Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
Yoshida Y; Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka, Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 Nov 03; Vol. 20 (1), pp. 1056. Date of Electronic Publication: 2020 Nov 03.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study
MeSH Terms:
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*administration & dosage
Human papillomavirus 16/*isolation & purification
Human papillomavirus 18/*isolation & purification
Papillomavirus Infections/*diagnosis
Adult ; Early Diagnosis ; Female ; Follow-Up Studies ; Healthy Volunteers ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/pharmacology ; Human papillomavirus 16/drug effects ; Human papillomavirus 18/drug effects ; Humans ; Japan ; Papillomavirus Infections/prevention & control ; Prospective Studies ; Research Design
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
Autorzy:
Rotstein Grein IH; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.; Department of Paediatrics, Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil.
Pinto NF; Department of Paediatrics, Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo, São Paulo, Brazil.
Lobo A; Department of Paediatrics, Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo, São Paulo, Brazil.
Groot N; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.
Sztajnbok F; Department of Paediatric Rheumatology, Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil.
da Silva CAA; Department of Paediatric Rheumatology, Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Paim Marques LB; Department of Paediatric Rheumatology, Hospital Infantil Albert Sabin, Fortaleza, Brazil.; Department of Paediatric Immunology and Rheumatology, University of Florida College of Medicine, Florida, USA.
Appenzeller S; Department of Paediatric Rheumatology, Universidade Estadual de Campinas, São Paulo, Brazil.
Islabão AG; Department of Paediatric Rheumatology, Hospital da Criança de Brasília José Alencar, Brasília, Brazil.
Magalhães CS; Department of Paediatric Rheumatology, Universidade Estadual Paulista, Botucatu, São Paulo, Brazil.
de Almeida RG; Department of Paediatric Rheumatology, Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Bica B; Department of Paediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Fraga M; Department of Paediatric Rheumatology, Hospital Infantil Darcy Vargas, São Paulo, Brazil.
da Fraga ACM; Department of Paediatric Rheumatology, Hospital Estadual Infantil Nossa Senhora da Glória, Vitória, Brazil.
Dos Santos MC; Department of Paediatric Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil.
Robazzi T; Department of Paediatric Rheumatology, Faculdade de Medicina da Universidade Federal da Bahia, Salvador, Brazil.
Terreri MTR; Department of Paediatric Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil.
Bandeira M; Department of Paediatric Rheumatology, Hospital Pequeno Príncipe, Curitiba, Brazil.
Pasmans H; Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Schepp R; Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
van der Klis F; Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
de Roock S; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.
Wulffraat N; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.
Pileggi G; Department of Paediatric Rheumatology, Faculdade de Medicina Barretos (FACISB), Barretos, Brazil.
Pokaż więcej
Źródło:
Lupus [Lupus] 2020 Jul; Vol. 29 (8), pp. 934-942. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antibodies, Viral/*blood
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Immunogenicity, Vaccine/*immunology
Lupus Erythematosus, Systemic/*immunology
Vaccination/*methods
Adolescent ; Brazil ; Case-Control Studies ; Child ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Lupus Erythematosus, Systemic/blood ; Male ; Papillomavirus Infections/prevention & control ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
Autorzy:
Mahumud RA; Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia.; School of Commerce, University of Southern Queensland, Toowoomba, QLD Australia.; Health Economics Research, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.; Health and Epidemiology Research, Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh.
Alam K; Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia.; School of Commerce, University of Southern Queensland, Toowoomba, QLD Australia.
Dunn J; Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia.; Cancer Research Centre, Cancer Council Queensland, Fortitude Valley, QLD, Australia.; Prostate Cancer Foundation of Australia, St Leonards NSW, Australia.
Gow J; Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia.; School of Commerce, University of Southern Queensland, Toowoomba, QLD Australia.; School of Accounting, Economics and Finance, University of KwaZulu-Natal, Durban, South Africa.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Oct 09; Vol. 14 (10), pp. e0223658. Date of Electronic Publication: 2019 Oct 09 (Print Publication: 2019).
Typ publikacji:
Journal Article
MeSH Terms:
Cost-Benefit Analysis*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*economics
Mass Vaccination/*economics
Papillomavirus Infections/*prevention & control
Uterine Cervical Neoplasms/*prevention & control
Australia ; Child ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/therapeutic use ; Humans ; Quality-Adjusted Life Years
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules.
Autorzy:
Lazcano-Ponce E; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.
Carnalla-Cortés M; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.
Barrientos-Gutiérrez T; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.
Torres-Ibarra L; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.
Cruz-Valdez A; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.
Salmerón J; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.; Centro de Investigación en Políticas, Población y Salud, Facultad de Medicina, Universidad Nacional Autónoma de México. Ciudad de México, México.
Hernández-Ávila M; Universidad de Guadalajara. Guadalajara, Jalisco, Mexico.
Pokaż więcej
Transliterated Title:
El efecto de un refuerzo de la vacuna tetravalente de VPH después de 51 meses: implicaciones para un esquema de vacunación extendido.
Źródło:
Salud publica de Mexico [Salud Publica Mex] 2018 Nov-Dic; Vol. 60 (6), pp. 666-673.
Typ publikacji:
Comparative Study; Equivalence Trial; Journal Article
MeSH Terms:
Immunization Schedule*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*administration & dosage
Immunization, Secondary/*methods
Immunogenicity, Vaccine/*immunology
Antibodies, Viral/biosynthesis ; Antibodies, Viral/blood ; Child ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/immunology ; Human papillomavirus 16/immunology ; Human papillomavirus 18/immunology ; Humans ; Mexico ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A retrospective case-control analysis of the efficacy of Gardasil vaccination in 28 patients with recurrent respiratory papillomatosis of the larynx.
Autorzy:
Milner TD; Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
Harrison A; Department of Otolaryngology, Head and Neck Surgery, Manchester Royal Infirmary, Manchester, UK.
Montgomery J; Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
MacGregor FB; Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
Buchanan MA; Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
MacKenzie K; Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
Pokaż więcej
Źródło:
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery [Clin Otolaryngol] 2018 Jun; Vol. 43 (3), pp. 962-965. Date of Electronic Publication: 2018 Feb 27.
Typ publikacji:
Journal Article
MeSH Terms:
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18*
Papillomavirus Infections/*epidemiology
Papillomavirus Infections/*surgery
Respiratory Tract Infections/*epidemiology
Respiratory Tract Infections/*surgery
Adolescent ; Adult ; Aged ; Child ; Female ; Humans ; Male ; Middle Aged ; Papillomavirus Infections/diagnosis ; Respiratory Tract Infections/diagnosis ; Retrospective Studies ; Young Adult
SCR Disease Name:
Recurrent respiratory papillomatosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
High human papillomavirus (HPV)-35 prevalence among South African women with cervical intraepithelial neoplasia warrants attention.
Autorzy:
Mbulawa ZZA; National Health Laboratory Service, Nelson Mandela Academic Hospital, Mthatha, South Africa.; Faculty of Health Sciences, Department of Laboratory Medicine and Pathology, Walter Sisulu University, Mthatha, South Africa.; UCT-MRC Gynaecological Cancer Research Centre, University of Cape Town, Cape Town, South Africa.; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Phohlo K; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Garcia-Jardon M; Faculty of Health Sciences, Department of Laboratory Medicine and Pathology, Walter Sisulu University, Mthatha, South Africa.
Williamson AL; UCT-MRC Gynaecological Cancer Research Centre, University of Cape Town, Cape Town, South Africa.; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Businge CB; Department of Obstetrics and Gynaecology, Nelson Mandela Academic Hospital, Mthatha, South Africa.; Faculty of Health Sciences, Department of Obstetrics and Gynaecology, Walter Sisulu University, Mthatha, South Africa.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Mar 09; Vol. 17 (3), pp. e0264498. Date of Electronic Publication: 2022 Mar 09 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Alphapapillomavirus*/genetics
Papillomavirus Infections*
Uterine Cervical Neoplasms*/pathology
Uterine Cervical Dysplasia*
Attention ; Female ; Genotype ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ; Humans ; Male ; Papillomaviridae/genetics ; Prevalence ; South Africa/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
Autorzy:
Hidalgo-Tenorio C; Infectious Disease Service, University Hospital Virgen de las Nieves, Granada, Spain. .
Ramírez-Taboada J; Infectious Disease Service, University Hospital Virgen de las Nieves, Granada, Spain.
Gil-Anguita C; Infectious Disease Service, University Hospital Virgen de las Nieves, Granada, Spain.
Esquivias J; Pathology Service, University Hospital Virgen de las Nieves, Granada, Spain.
Omar-Mohamed-Balgahata M; Infectious Disease Unit of the Hospital Ciudad de Jaén, Jaén, Spain.
SamPedro A; Microbiology Service, University Hospital Virgen de las Nieves, Granada, Spain.
Lopez-Ruz M; Infectious Disease Service, University Hospital Virgen de las Nieves, Granada, Spain.
Pasquau J; Infectious Disease Service, University Hospital Virgen de las Nieves, Granada, Spain.
Pokaż więcej
Źródło:
AIDS research and therapy [AIDS Res Ther] 2017 Jul 18; Vol. 14 (1), pp. 34. Date of Electronic Publication: 2017 Jul 18.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Antibodies, Viral/*blood
Anus Neoplasms/*prevention & control
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*adverse effects
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Human papillomavirus 16/*immunology
Human papillomavirus 18/*immunology
Papillomavirus Infections/*prevention & control
Adult ; Anal Canal/virology ; Anus Neoplasms/virology ; CD4 Lymphocyte Count ; Coinfection/virology ; Double-Blind Method ; HIV Infections/virology ; Homosexuality, Male ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/therapeutic use ; Humans ; Male ; Papillomavirus Infections/immunology ; Papillomavirus Infections/virology ; Placebos/therapeutic use ; Spain ; Viral Load/immunology ; Viremia/virology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
High human papillomavirus prevalence among females attending high school in the Eastern Cape Province of South Africa.
Autorzy:
Mbulawa ZZA; National Health Laboratory Service, Nelson Mandela Academic Hospital, Mthatha, South Africa.; Department of Laboratory Medicine and Pathology, Walter Sisulu University, Mthatha, South Africa.; SAMRC/UCT Gynaecological Cancer Research Centre, University of Cape Town, Cape Town, South Africa.; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Somdyala NI; South African Medical Research Council, Burden of Disease Research Unit, Cape Town, South Africa.
Mabunda SA; SAMRC/UCT Gynaecological Cancer Research Centre, University of Cape Town, Cape Town, South Africa.; The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Williamson AL; SAMRC/UCT Gynaecological Cancer Research Centre, University of Cape Town, Cape Town, South Africa.; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Jun 18; Vol. 16 (6), pp. e0253074. Date of Electronic Publication: 2021 Jun 18 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Alphapapillomavirus/*classification
Papillomavirus Infections/*epidemiology
Students/*statistics & numerical data
Adolescent ; Alphapapillomavirus/genetics ; Alphapapillomavirus/isolation & purification ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ; Humans ; Mass Vaccination ; Papillomavirus Infections/prevention & control ; Population Surveillance ; Prevalence ; Risk Assessment ; Sexual Behavior ; South Africa/epidemiology ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years.
Autorzy:
Hidalgo-Tenorio C; Infectious Disease Department, Hospital Universitario Virgen de las Nieves Granada, 18014 Granada, Spain.
Pasquau J; Infectious Disease Department, Hospital Universitario Virgen de las Nieves Granada, 18014 Granada, Spain.
Omar-Mohamed M; Infectious Disease Unit, Complejo Hospitalario Jaén, 23007 Jaén, Spain.
Sampedro A; Microbiology Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
López-Ruz MA; Infectious Disease Department, Hospital Universitario Virgen de las Nieves Granada, 18014 Granada, Spain.
López Hidalgo J; Pathology Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
Ramírez-Taboada J; Infectious Disease Department, Hospital Universitario Virgen de las Nieves Granada, 18014 Granada, Spain.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Jan 20; Vol. 13 (2). Date of Electronic Publication: 2021 Jan 20.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Viral/*blood
Anus Neoplasms/*prevention & control
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*administration & dosage
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*prevention & control
Adult ; Anal Canal/virology ; Anus Neoplasms/virology ; CD4 Lymphocyte Count ; Coinfection/virology ; HIV Infections/virology ; Homosexuality, Male ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Papillomavirus Infections/immunology ; Papillomavirus Infections/virology ; Regression Analysis ; Sexual and Gender Minorities ; Spain ; Viral Load/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations.
Autorzy:
Bosco L; Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Biology and Genetics, University of Palermo, Palermo, Italy.
Serra N; Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy.
Fasciana T; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) 'G. D'Alessandro', University of Palermo, Via del Vespro, 133, 90127, Palermo, Italy.
Pistoia D; UOC of Microbiology, Virology and Parasitology, Polyclinic Hospital, Palermo, Italy.
Vella M; Section of Urology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Di Gregorio L; UOC of Urology and Extracorporeal Lithotripsy, Polyclinic Hospital, Palermo, Italy.
Schillaci R; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) 'G. D'Alessandro', University of Palermo, Via del Vespro, 133, 90127, Palermo, Italy.
Perino A; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) 'G. D'Alessandro', University of Palermo, Via del Vespro, 133, 90127, Palermo, Italy.
Calagna G; Villa Sofia Cervello Hospital, University of Palermo, Palermo, Italy.
Firenze A; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) 'G. D'Alessandro', University of Palermo, Via del Vespro, 133, 90127, Palermo, Italy.
Capra G; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) 'G. D'Alessandro', University of Palermo, Via del Vespro, 133, 90127, Palermo, Italy. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Feb 18; Vol. 11 (1), pp. 4096. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji:
Journal Article
MeSH Terms:
Papillomavirus Infections/*prevention & control
Papillomavirus Vaccines/*therapeutic use
Adult ; Aged ; Case-Control Studies ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/therapeutic use ; Humans ; Male ; Middle Aged ; Papillomaviridae/genetics ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/pathology ; Papillomavirus Infections/transmission ; Sicily/epidemiology ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer.
Autorzy:
Zhang L; Department of Medicine, Immunology and Allergy Unit, Karolinska Institutet, Stockholm, Sweden.
Zirakzadeh AA; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Rosvall J; Department of Urology, Stockholm South General Hospital, Karolinska Institutet, Stockholm, Sweden.
Hedlund M; Department of Urology, UroClinic® prostatacenter, Sophiahemmet, Stockholm, Sweden.
Hu PS; Cancer Biotherapy Center, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Riklund K; Department of Radiation Sciences, Umeå University, Umeå, Sweden.
Sherif A; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. .
Winqvist O; Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło:
Investigative and clinical urology [Investig Clin Urol] 2021 Jan; Vol. 62 (1), pp. 39-46. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji:
Journal Article
MeSH Terms:
Antigens, Neoplasm/*immunology
Lymph Nodes/*immunology
Papillomaviridae/*immunology
Penile Neoplasms/*immunology
Penile Neoplasms/*virology
Aged ; Aged, 80 and over ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/immunology ; Humans ; Immunophenotyping ; Lymphocyte Activation ; Male ; Middle Aged ; Papillomaviridae/genetics ; Viral Proteins/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Human Papillomavirus (HPV) and the quadrivalent HPV Vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance.
Autorzy:
Gomes JM; Disciplina de Ginecologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Silva BM; Disciplina de Ginecologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Santos EFS; Study Design and Scientific Writing Laboratory at ABC Medical School, Santo André, SP, Brazil.
Kelly PJ; School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas City, MO, United States of America.
Costa AS; Disciplina de Ginecologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Takiuti AD; Disciplina de Ginecologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
de Abreu LC; Study Design and Scientific Writing Laboratory at ABC Medical School, Santo André, SP, Brazil.
Soares Júnior JM; Disciplina de Ginecologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Baracat EC; Disciplina de Ginecologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Sorpreso ICE; Disciplina de Ginecologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2020 Nov 12; Vol. 15 (11), pp. e0241674. Date of Electronic Publication: 2020 Nov 12 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Health Knowledge, Attitudes, Practice*
Patient Acceptance of Health Care*
Papillomavirus Infections/*prevention & control
Vaccination/*psychology
Adolescent ; Adult ; Brazil ; Female ; Health Education/statistics & numerical data ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/therapeutic use ; Humans ; Male ; Papillomavirus Infections/psychology ; Parents/psychology ; Vaccination/statistics & numerical data
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Autorzy:
Östensson E; Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Fröberg M; Department of Neurobiology, Care Science and Society, Centre for Family Medicine and Community Medicine, Karolinska Institutet, Stockholm, Sweden.
Leval A; Department of Medicine, Infectious Disease Unit, Karolinska Institutet, Stockholm, Sweden; Department of Communicable Disease Control and Prevention for Stockholm County, Stockholm, Sweden.
Hellström AC; Department of Oncology-Pathology, Karolinska University Hospital-Solna, Karolinska Institutet, Stockholm, Sweden.
Bäcklund M; Department of Medicine, Solna (MedS), K2, Karolinska Institutet, Stockholm, Sweden.
Zethraeus N; Medical Management Centre (MMC), Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, Stockholm, Sweden.
Andersson S; Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Sep 23; Vol. 10 (9), pp. e0139062. Date of Electronic Publication: 2015 Sep 23 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Health Care Costs/*statistics & numerical data
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*therapeutic use
Papillomavirus Infections/*economics
Adult ; Condylomata Acuminata/economics ; Condylomata Acuminata/prevention & control ; Condylomata Acuminata/therapy ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/economics ; Humans ; Middle Aged ; Papillomavirus Infections/complications ; Papillomavirus Infections/prevention & control ; Papillomavirus Infections/therapy ; Sweden/epidemiology ; Uterine Cervical Dysplasia/economics ; Uterine Cervical Dysplasia/prevention & control ; Uterine Cervical Dysplasia/therapy ; Uterine Cervical Neoplasms/economics ; Uterine Cervical Neoplasms/prevention & control ; Uterine Cervical Neoplasms/therapy ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Circulating CXCR5⁺CD4⁺ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines.
Autorzy:
Matsui K; Human Papillomavirus (HPV) Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Adelsberger JW; AIDS Monitoring Laboratory, Clinical Service Program, Applied and Developmental Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Kemp TJ; Human Papillomavirus (HPV) Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Baseler MW; AIDS Monitoring Laboratory, Clinical Service Program, Applied and Developmental Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Ledgerwood JE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Pinto LA; Human Papillomavirus (HPV) Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Sep 02; Vol. 10 (9), pp. e0137195. Date of Electronic Publication: 2015 Sep 02 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Immunologic Memory*
Alphapapillomavirus/*immunology
B-Lymphocytes/*immunology
CD4-Positive T-Lymphocytes/*immunology
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*administration & dosage
Papillomavirus Vaccines/*administration & dosage
Receptors, CXCR5/*blood
Antibodies, Viral/blood ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/immunology ; Humans ; Influenza Vaccines/administration & dosage ; Influenza Vaccines/immunology ; Papillomavirus Vaccines/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.
Autorzy:
Mboumba Bouassa RS; Laboratoire de virologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Ecole Doctorale Régionale en Infectiologie Tropicale, Franceville, Gabon.; Université Paris Descartes, Paris Sorbonne Cité, Paris, France.; INSERM UMR_S970, Immunothérapie et traitement anti-angiogénique en cancérologie, Paris Centre de Recherche Cardiovasculaire (PARCC), hôpital européen Georges Pompidou, AP-HP, Paris, France.
Péré H; Laboratoire de virologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Université Paris Descartes, Paris Sorbonne Cité, Paris, France.; INSERM UMR_S970, Immunothérapie et traitement anti-angiogénique en cancérologie, Paris Centre de Recherche Cardiovasculaire (PARCC), hôpital européen Georges Pompidou, AP-HP, Paris, France.
Gubavu C; Service des maladies infectieuses et tropicales, Centre hospitalier régional d'Orléans and Centre Gratuit d'Information, de Dépistage et de Diagnostic (CEGIDD) d'Orléans, Orléans, France.
Prazuck T; Service des maladies infectieuses et tropicales, Centre hospitalier régional d'Orléans and Centre Gratuit d'Information, de Dépistage et de Diagnostic (CEGIDD) d'Orléans, Orléans, France.
Jenabian MA; Département des Sciences Biologiques et Centre de Recherche BioMed, Université du Québec à Montréal (UQAM), Montreal, Quebec, Canada.
Veyer D; Laboratoire de virologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Meye JF; Service de Gynécologie Obstétrique, Centre Hospitalo-Universitaire d'Agondjé et Faculté de Médecine de Libreville, Université des Sciences de la Santé, Libreville, Gabon.
Touzé A; UMRINRA ISP 1282, Equipe Biologie des infections à polyomavirus, Université de Tours, Tours, France.
Bélec L; Laboratoire de virologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Ecole Doctorale Régionale en Infectiologie Tropicale, Franceville, Gabon.; Université Paris Descartes, Paris Sorbonne Cité, Paris, France.; INSERM UMR_S970, Immunothérapie et traitement anti-angiogénique en cancérologie, Paris Centre de Recherche Cardiovasculaire (PARCC), hôpital européen Georges Pompidou, AP-HP, Paris, France.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2020 May 18; Vol. 15 (5), pp. e0233084. Date of Electronic Publication: 2020 May 18 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Viral/*metabolism
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*diagnosis
Uterine Cervical Neoplasms/*virology
Adult ; Africa South of the Sahara/ethnology ; Antibodies, Viral/blood ; Cervix Uteri/immunology ; Early Detection of Cancer ; Emigrants and Immigrants/statistics & numerical data ; Female ; France/ethnology ; Human papillomavirus 16/immunology ; Human papillomavirus 18/immunology ; Humans ; Middle Aged ; Papillomavirus Infections/immunology ; Uterine Cervical Neoplasms/immunology ; Vagina/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 94

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies